Plus Therapeutics, Inc.
PSTV
$0.59
$0.00-0.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.40M | 1.39M | 1.06M | 1.41M | 1.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.40M | 1.39M | 1.06M | 1.41M | 1.46M |
| Cost of Revenue | 2.44M | 1.25M | 1.76M | 2.19M | 2.86M |
| Gross Profit | -1.04M | 144.00K | -697.00K | -774.00K | -1.40M |
| SG&A Expenses | 3.44M | 1.68M | 2.84M | 3.13M | 2.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.88M | 2.93M | 4.60M | 5.31M | 5.26M |
| Operating Income | -4.48M | -1.54M | -3.54M | -3.90M | -3.80M |
| Income Before Tax | -4.42M | 5.15M | -17.40M | -3.90M | -2.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.42M | 5.15M | -17.40M | -3.90M | -2.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.42M | 5.15M | -17.40M | -3.90M | -2.87M |
| EBIT | -4.48M | -1.54M | -3.54M | -3.90M | -3.80M |
| EBITDA | -4.41M | -1.46M | -3.39M | -3.70M | -3.60M |
| EPS Basic | -0.04 | 0.02 | -29.52 | -0.50 | -0.37 |
| Normalized Basic EPS | -0.03 | 0.07 | -23.88 | -0.31 | -0.23 |
| EPS Diluted | -0.04 | -0.01 | -29.52 | -0.50 | -0.37 |
| Normalized Diluted EPS | -0.03 | 0.02 | -23.88 | -0.31 | -0.23 |
| Average Basic Shares Outstanding | 107.43M | 48.39M | 455.40K | 7.86M | 7.86M |
| Average Diluted Shares Outstanding | 107.43M | 209.16M | 455.40K | 7.86M | 7.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |